Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Aip_ecm_morsels_xm
Lab-grown decellularized ECM morsels (injectable matrix therapy)

Injectable human ECM morsels for HF and IPF—Slater-seeded Brown spinout.

Slater $375K + BBII—large-animal PoP before Heartseed-class Series A.

Entity: XM TherapeuticsPatents: 5Stage: preclinical proof of principle
US20230348859A1WO2022140530A1US8361781B2US11286451B2US12435312B2PMID 39705507
Open dossier
Tier Aip_dendritic_ad_mindimmune
Peripheral dendritic-cell blockade for Alzheimer's (MITI-101)

Block dendritic recruitment to AD brain—$30M Series A with RI Hub IND grant.

MITI-101 mAb post–Series A—co-invest or extension with Slater/RightHill in syndicate.

Entity: MindImmunePatents: 3Stage: preclinical ind enabling
US20210181185A1US10124010B2US10238654B2PMID 38705533
Open dossier
Tier Aip_pax_aav_vegf_tendon
AAV2–VEGF gene therapy for tendon & ligament repair (PAX-001)

One-shot gene therapy at repair—faster, stronger tendon healing than surgery alone.

RIH-origin patents + ~$1.7M seed + RILSH LIFT for IND—physician-chairman Liu MD with pre-IND complete.

Entity: Pax TherapeuticsPatents: 1Stage: preclinical ind enabling
WO2019146830A1Source
Open dossier
Tier APatent gapgap_smurf2_oncology
SMURF2–HIF1α oncology

HIF-pathway oncology with Welireg-scale commercial proof—harvest El-Deiry estate.

R01CA173453 + SMURF-Tx Providence—Slater seed after biomarker PoC.

Entity: SMURF-TherapeuticsPatents: 3Stage: preclinical grant
WO2024192252A1US20230183356A1US20230219957A1R01CA173453PMID 39697237PMID 34611473
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.